№ lp_1_2_27092
File format: docx
Character count: 33957
File size: 165 KB
A UK Health Security Agency (UKHSA) publication providing guidelines for administering the meningococcal group B vaccine (4CMenB) under specific conditions in England.
Year:
2025
Region / City:
England
Topic:
Meningococcal Disease, Vaccination
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency
Target Audience:
Healthcare practitioners, NHS organizations
Period of validity:
1 July 2025 - 28 February 2028
Approval Date:
2 June 2025
Amendments Date:
11 December 2024, 7 December 2022, 28 January 2021, 21 December 2018, 24 April 2018, 3 February 2017, 21 July 2015
Note:
Context
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region / City:
United Kingdom
Topic:
Meningococcal Disease, Ciprofloxacin, Public Health
Document Type:
Clinical Guidance
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
Shilan Ghafoor, Dr. Shamez Ladhani, Kate Wedgwood
Target Audience:
Healthcare Practitioners, Public Health Authorities
Period of Validity:
From 20 October 2025
Approval Date:
10 October 2025
Expiry Date:
19 October 2028
Review Date:
19 October 2027
Year:
2023
Region / City:
Massachusetts
Topic:
Meningococcal disease, Vaccination requirements
Document type:
Health advisory
Institution:
Massachusetts Department of Public Health
Author:
Massachusetts Department of Public Health
Target audience:
College and residential school students, Parents and legal guardians
Period of validity:
Ongoing
Approval date:
Not specified
Amendment date:
Not specified
Year:
2025
Region / City:
England
Topic:
Immunisation, Vaccination
Document Type:
Patient Group Direction (PGD)
Organization:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target Audience:
Healthcare practitioners (registered)
Period of validity:
1 August 2025 - 1 August 2027
Approval Date:
9 June 2025
Review Date:
1 February 2027
Amendment Date:
7 July 2025
Year:
2025
Region / city:
England
Topic:
Vaccination
Document Type:
Patient Group Direction (PGD)
Authorizing Body:
UK Health Security Agency (UKHSA)
Target Audience:
Healthcare professionals involved in immunization
Validity Period:
31 July 2025 – 31 December 2027
Review Date:
30 June 2027
Amendment History:
v1.0 to v6.0
Approval Date:
2 June 2025
Year:
2024
Region / city:
England
Theme:
Vaccination, Meningococcal Disease
Document type:
Patient Group Direction (PGD)
Institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Mary Ramsay, David Green
Target audience:
Healthcare practitioners
Period of validity:
From 28 February 2025 to 28 February 2028
Approval date:
11 December 2024
Revision date:
7 December 2022
Expiry date:
28 February 2028
Content changes:
Minor rewording and updates for clarity and consistency, updated qualifications and professional registration
Purpose:
Facilitates the administration of the meningococcal group B vaccine in individuals with increased risk from Neisseria meningitidis group B in the UK
Year:
2017
Region / city:
Australia
Theme:
Meningococcal Vaccination
Document Type:
Application for Vaccine Listing
Organization / institution:
National Immunization Program (NIP)
Author:
Pfizer Australia Pty Ltd
Target Audience:
Health professionals, adolescents, school-based vaccination program administrators
Validity Period:
Not specified
Approval Date:
29 August 2013
Amendment Date:
Not specified
Note:
Contextual description
Year:
2020
Region / City:
United Kingdom, London
Subject:
Meningococcal disease, vaccination
Document Type:
Research article
Institution:
St George’s University of London, Public Health England
Author:
Catherine Isitt, Catherine A Cosgrove, Mary E Ramsay, Shamez N Ladhani
Target Audience:
Healthcare professionals, researchers
Period of validity:
Ongoing
Date of approval:
2013
Date of modifications:
None specified
Year:
2017
Region / city:
Northern Territory, South Australia, Western Australia
Topic:
Meningococcal Vaccination
Document Type:
Health Information Sheet
Organization:
Western Australia Department of Health
Author:
Western Australia Department of Health
Target Audience:
Community members in remote regions of Western Australia
Effective Period:
Ongoing during the MenW outbreak response
Approval Date:
October 2017
Modification Date:
Not specified
Year:
2017
Country:
Australia
Programme:
Australian Meningococcal Surveillance Programme (AMSP)
Coordinating body:
National Neisseria Network
Funding body:
Australian Government Department of Health
Authors:
Monica M Lahra; Rodney Enriquez; CR Robert George
Subject:
Invasive meningococcal disease surveillance
Pathogen:
Neisseria meningitidis
Data sources:
National Neisseria Network laboratories; National Notifiable Diseases Surveillance System
Number of laboratory-confirmed cases:
374
Number of notified cases:
379
Primary serogroups reported:
B; W; Y; C
Peak incidence period:
1 July – 30 September 2017
Geographical coverage:
All Australian states and territories
Antimicrobial susceptibility testing:
Penicillin; Ceftriaxone; Ciprofloxacin; Rifampicin
Type of document:
Annual epidemiological surveillance report
Year:
2025
Region:
Washington State, United States
Topic:
Meningococcal disease and vaccination information
Document type:
Public health informational notice
Issuing organization:
Washington State Department of Health
Legal basis:
RCW 70.54.370
Target audience:
First-time enrolled college students
Purpose:
Required educational information prior to enrollment
Publication date:
April 2025
Document code:
DOH 348-636
Distribution format:
Electronic information notice
Subject areas:
Disease transmission, symptoms, treatment, prevention, vaccination
Related institutions:
Colleges and universities in Washington State
Year:
2023
Region / City:
Victoria, Australia
Topic:
Vaccination Program
Document Type:
Consent Form
Organization / Institution:
Department of Health, Victorian Government
Author:
Unknown
Target Audience:
Parents or guardians of students in secondary schools
Period of Effectiveness:
Ongoing
Approval Date:
October 2023
Date of Changes:
October 2023
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / city:
England
Topic:
Influenza immunisation
Document type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Jamie Lopez-Bernal, Greta Hayward
Target audience:
Healthcare practitioners, NHS organisations
Period of validity:
From 1 September 2025 to 1 April 2026
Approval date:
3 July 2025
Revision history:
Updated annually, latest update 9 July 2025
Reference no:
HPV (GBMSM) PGD
Version no:
v5.0
Valid from:
1 September 2025
Review date:
1 April 2028
Expiry date:
1 September 2028
Author:
Suki Hunjunt, Sharif Ismail, David Green
Region / city:
England
Target audience:
Healthcare practitioners administering HPV vaccine to GBMSM
Type of document:
Patient Group Direction
Organisation:
UK Health Security Agency (UKHSA)
Date of approval:
17 July 2025
Date of modifications:
16 July 2025
Context:
A formal Patient Group Direction for the administration of HPV vaccine to GBMSM, detailing legal, clinical, and procedural requirements for healthcare practitioners in England.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025
Year:
2024
Region / city:
England
Topic:
Vaccination
Document type:
Patient Group Direction
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, David Green
Target audience:
Registered healthcare practitioners
Period of validity:
10 October 2024 - 30 April 2027
Approval date:
4 October 2024
Amendments date:
9 October 2024
Note:
Year
Organization / Institution:
NHS Scotland
Author:
Dr Laura Ryan, Dr John McAnaw, Mr Jim Miller
Target Audience:
Qualified health professionals within NHS Scotland
Changes History:
Eligibility age extended, new conditions added, clarifications made
Clinical Situation:
Acute uncomplicated urinary tract infection (UTI) in non-pregnant females aged 16 years and over.
Year:
2024
Region / City:
Scotland
Topic:
Pharmaceutical Guidelines
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
NHS Scotland
Author:
Dr. Ronald Cook, Dr. John McAnaw
Target Audience:
Community Pharmacists
Effective Date:
20th February 2024
Expiry Date:
19th February 2027